The KLOTHO gene encodes an anti-aging protein named after the Greek goddess who spins the thread of life. Mice deficient in klotho exhibit accelerated aging phenotypes including atherosclerosis, osteoporosis, and shortened lifespan¹¹ Mice deficient in klotho exhibit accelerated aging phenotypes including atherosclerosis, osteoporosis, and shortened lifespan
Kuro-o M et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997, establishing klotho as a fundamental regulator of longevity. The rs9536314 variant tags the KL-VS haplotype, six single nucleotide polymorphisms in perfect linkage disequilibrium that alter klotho protein function and circulating levels.

This variant exhibits a rare phenomenon called overdominance or heterozygote advantage²² overdominance or heterozygote advantage
a genetic pattern where having one copy of a variant is beneficial, but having two copies is detrimental.

KL-VS heterozygosity occurs in about 20-25% of the population and is associated with higher cognitive performance across the adult lifespan, larger frontotemporal gray matter volume, and lower mortality . In contrast, homozygotes for the KL-VS allele show a 2.59-fold survival disadvantage across three distinct populations .

The Mechanism

The F352V substitution (phenylalanine to valine at position 352) occurs at a completely conserved amino acid in the klotho protein's first internal repeat domain.

The level of secreted klotho is increased in KL-VS heterozygotes and conversely reduced in KL-VS homozygotes compared to major allele homozygotes . This creates a U-shaped dose-response curve: one copy increases circulating klotho (protective), while two copies decrease it (harmful).

The variant alters klotho's trafficking and catalytic activity.

In vitro studies show the F352V and C370S substitutions lead to alterations in processing as seen by differences in shedding and half-life .

In transient transfection assays, secreted levels of klotho harboring V352 are reduced 6-fold , suggesting the homozygous state produces a klotho protein with impaired secretion.

Klotho acts as a co-receptor for fibroblast growth factor 23 (FGF23), regulating calcium and phosphate homeostasis.

Transgenic overexpression of klotho in mice enhances behavioral testing performance through augmentation of NMDAR-related effects, including upregulated FOS expression after learning and memory tasks and amplified LTP response in the hippocampus .

The Evidence

Longevity Studies:

In Ashkenazi Jews, heterozygous advantage for longevity was observed for individuals ≥79 years of age, with a 1.57-fold increased odds ratio for 5-year survival in two independent populations .

Prospective analysis using Cox regression indicates wild-type individuals have a 2.15-fold and homozygous KL-VS individuals a 4.49-fold increase in relative risk for mortality .

Cognitive Function:

A lifespan-extending variant of the human KLOTHO gene, KL-VS, is associated with enhanced cognition in heterozygous carriers across three independent cohorts totaling 718 aging individuals without dementia.

In adults, individuals who are heterozygous for the KL-VS allele outperform non-carriers on measures of global cognition including language, executive function, visuospatial function, learning and memory .

However, the cognitive benefits appear age-dependent.

In 1,480 Danes aged 92-100 years, heterozygotes for KL-VS had poorer cognitive function than noncarriers . This suggests the protective effects may diminish or reverse at very advanced ages.

Alzheimer's Disease:

KL-VS heterozygotes showed lower cross-sectional and longitudinal increase in tau-PET per unit increase in amyloid-PET compared to non-carriers .

KL-VS heterozygosity was related to better memory functions in amyloid-positive participants and this association was mediated by lower tau-PET .

KL-VS heterozygote status slows down the progression of cognitive decline related to Alzheimer's disease, and this effect is dependent on the absence of the APOE ε4 allele .

Cardiovascular Effects:

Cross-sectional and prospective studies confirm KL-VS heterozygotes have higher HDL cholesterol and lower systolic blood pressure; the allele confers a heterozygous advantage with a marked homozygous disadvantage for these outcomes .

The GG and GT genotypes are more represented among salt-sensitive hypertensive patients; carriers of the G allele showed a less steep pressure-natriuresis relationship .

Practical Implications

For heterozygotes (GT genotype), the evidence suggests a meaningful protective effect against cognitive decline and age-related conditions, particularly before very advanced age. The elevated circulating klotho associated with heterozygosity may act as a buffer against neurodegeneration. However, these benefits may not extend linearly into extreme old age.

For homozygotes (GG genotype), the consistent mortality disadvantage and reduced klotho levels warrant clinical attention. These individuals may benefit from interventions that support healthy aging pathways, though no specific klotho-targeted therapies are currently available. Monitoring cardiovascular risk factors and cognitive function may be particularly important.

The paradoxical age-dependency raises important questions. Studies in middle-aged and elderly adults (50s-80s) consistently show heterozygote cognitive advantages, while studies in the oldest-old (90+) show the opposite pattern. This may reflect survival bias, changing cellular environments with extreme age, or genuine biological transitions in klotho's effects.

Interactions

The KL-VS haplotype consists of six SNPs in perfect linkage disequilibrium, with rs9527025 (C370S) always co-occurring with rs9536314 (F352V). These two amino acid substitutions work together to alter klotho protein function.

An important gene-gene interaction exists between KLOTHO KL-VS and APOE ε4. In Alzheimer's disease patients, KL-VS heterozygosity confers slower cognitive decline in APOE ε4 non-carriers but not in ε4 carriers. This suggests the protective effects of elevated klotho may be overwhelmed or modified by the strong pro-degenerative effects of APOE ε4. For individuals who are KL-VS heterozygotes and lack APOE ε4, the combination provides substantial protection against cognitive decline, while KL-VS heterozygotes who carry APOE ε4 lose this advantage.

The RAD50 gene¹¹ RAD50 gene
RAD50 (RAD50 double-strand break repair protein) encodes an ATPase component of the MRN complex involved in DNA damage repair — but at chromosome 5q31.1, its introns house the locus control region that coordinates IL-4, IL-5, and IL-13 expression in Th2 immune cells, making it a key regulatory scaffold for the Th2 cytokine cluster sits at one of the most replicated atopy-susceptibility loci in the human genome. At position chr5:132,565,533, rs2244012 lies within intron 2 of RAD50, 5q31.1 — a chromosomal address that genomicists have been tracking since the first genome-wide scans for IgE and asthma susceptibility. The Li et al. (2010) GWAS²² Li et al. (2010) GWAS
genome-wide association study of 473 patients with severe or difficult-to-treat asthma versus 1,892 general population controls; 292,443 SNPs genotyped; top hit rs2244012 in intron 2 of RAD50 reached P=3.04×10⁻⁷ at the 5q31 locus identified rs2244012 as the top GWAS hit at this locus — the single SNP with the strongest genome-wide association signal for asthma in the 5q31 region. The G allele tags a regulatory haplotype in the Th2 locus control region that amplifies the output of IL-4, IL-5, and IL-13 — the cytokines that collectively orchestrate allergic inflammation.

The Mechanism

The introns of RAD50 are not just splice-junction filler. A landmark study by Lee et al. (2003)³³ Lee et al. (2003)
Lee GR et al. Immunity 2003; BAC transgenic mice carrying IL4-luciferase reporters showed that a 25 kb fragment within the RAD50 gene confers Th2-specific, copy-number-dependent expression of IL-4 and IL-13 — defining this region as a locus control region (LCR) governing the adjacent Th2 cytokine gene cluster identified a 25 kb region within RAD50 as the Th2 locus control region (TH2-LCR)⁴⁴ Th2 locus control region (TH2-LCR)
a cluster of four DNase I hypersensitive sites (RHS4–RHS7) that loop chromosomally to simultaneously activate IL-4, IL-5, and IL-13 transcription when a T cell commits to the Th2 lineage; mechanistically analogous to the beta-globin LCR that governs globin gene switching during red blood cell development — a regulatory element that coordinates simultaneous transcription of IL-4, IL-5, and IL-13 when T cells commit to the Th2 lineage.

Within this control region, the rs2244012 G allele tags a haplotype that includes functional regulatory variants. One such neighbor, rs2240032 in the RHS7 element of the TH2-LCR, shows allele-specific binding of SMAD3 and SP1⁵⁵ allele-specific binding of SMAD3 and SP1
Kretschmer et al. Allergy 2014; differential transcription-factor binding at RHS7 alters methylation of the IL13 promoter and shifts IL4 and RAD50 expression in an allele-specific manner and alters DNA methylation at the IL13 promoter beginning in cord blood and persisting into childhood — a mechanism that links genotype at birth to measurable epigenetic differences in Th2 cytokine regulation years later. When this regulatory hub is in the more active state, Th2-committed T cells produce higher pulses of IL-13 and IL-4 on allergen stimulation. IL-13 then acts directly on airway epithelium and smooth muscle to drive mucus hypersecretion and airway hyperresponsiveness; IL-4 drives B-cell class switching to IgE, sensitizing mast cells to allergens systemically.

The Evidence

rs2244012 rose to the top of the 5q31 GWAS signal in the Li et al. (2010)⁶⁶ Li et al. (2010)
Li X et al. J Allergy Clin Immunol 2010; 292,443 SNPs genotyped; 473 TENOR patients with severe asthma vs 1,892 Illumina general population controls study — the first large-scale GWAS to genotype the RAD50-IL13 region at the density needed to resolve the 5q31 signal. Multiple SNPs in the region reached significance, but rs2244012 carried the strongest p-value at P=3.04×10⁻⁷, implicating intron 2 of RAD50 as the locus index variant for asthma in this cohort.

Fine-mapping by Sharma et al. (2014)⁷⁷ Sharma et al. (2014)
Sharma V et al. Allergy 2014; 64 polymorphisms across three IgE loci (1q23, 5q31, 12q13) in >1,300 German children; 5q31 confirmed as a major IgE determinant; risk alleles at all three loci together elevate IgE risk fourfold in more than 1,300 German children confirmed 5q31 (RAD50-IL13 and IL4) as one of three major determinants of total serum IgE. Associations at this locus are primarily with mild-to-moderate IgE elevation — the 5q31 signal reflects a common population-level Th2 amplifier rather than a rare high-penetrance risk factor.

The atopic spectrum of this locus extends beyond asthma. The 5q31.1 region maps to the IL4/KIF3A locus in a meta-analysis by Marenholz et al. (2015)⁸⁸ meta-analysis by Marenholz et al. (2015)
Nature Commun 2015; 12 populations, 2,428 cases of infantile eczema progressing to childhood asthma, 17,034 controls; seven genome-wide significant loci for the atopic march identified; IL4/KIF3A at 5q31.1 confirmed identifying seven loci for the atopic march — the progression from eczema to food allergy to asthma to allergic rhinitis — confirming that the 5q31 signal drives not just asthma risk but the full sequential atopic phenotype.

Replication has been mixed by population: the Li et al. finding was replicated in Pakistani children (Ghani et al. 2025, PMID 41001556), while a Han Chinese pediatric study (Li et al. 2016, PMID 26365633) found no association — population-specific genetic backgrounds and differing LD structures likely explain the discrepancy. The G allele shows dramatically higher frequency in African ancestry (~61%) compared to European (~22%) and East Asian (~18%) populations, consistent with a common regulatory haplotype that is ancestrally enriched in African populations.

Practical Implications

The G allele at rs2244012 lowers the threshold at which allergen exposure triggers sensitization and sustained allergic inflammation. The mechanism is upstream Th2 cytokine amplification — each G allele shifts the IL-13/IL-4 output capacity of Th2 cells upward, raising baseline IgE and making mast cell sensitization faster and more durable. Children carrying the G allele who develop early eczema face elevated biological risk for the full atopic march; adults who have never developed overt atopy may still carry subclinically elevated IgE that sensitizes them to new occupational or environmental allergens more readily than AA individuals.

Therapeutically, the biology is increasingly tractable: dupilumab (anti-IL-4Rα, blocking both IL-4 and IL-13), tralokinumab (anti-IL-13), and cendakimab (anti-IL-13Rα1) directly counter the cytokine output amplified by this genotype. G allele carriers with refractory atopic disease are biologically well-matched to this drug class.

Interactions

rs2244012 lies within the same 5q31.1 RAD50/TH2-LCR haplotype block as rs2040704 and rs2240032 — these variants are in strong linkage disequilibrium and collectively tag the Th2 locus control region regulatory haplotype. The rs2040704 G allele at the TH2-LCR enhancer hub and rs2244012 G allele in RAD50 intron 2 likely co-segregate on the same risk haplotype, making their combined effect equivalent to carrying a single high-activity TH2-LCR configuration.

Carriers who also carry rs20541-A (IL13 R130Q, increased IL-13 bioavailability) face a double hit: elevated IL-13 production from this locus control region variant, combined with reduced IL-13 decoy receptor clearance from the downstream coding variant. The combination of rs1801275 (IL-4Rα R576Q) with the G allele at this locus creates a production × receptor synergy that is particularly relevant to dupilumab pharmacogenomics.

Deep inside every cell, lysosomes act as the cell's recycling plant — breaking down old proteins, clearing misfolded aggregates, and recycling the parts. Maintaining the right internal pH (around 4.5–5.0) is essential for the digestive enzymes inside to work. TMEM175 encodes a lysosomal ion channel¹¹ lysosomal ion channel
proton-activated, proton-selective K+/H+ channel that fine-tunes lysosomal acidity — a molecular pressure-relief valve. The rs34311866 C allele introduces a methionine-to-threonine substitution at position 393 that partially disables this valve, with consequences that reach all the way to Parkinson's disease risk.

The Mechanism

The M393T substitution reduces channel current amplitude²² The M393T substitution reduces channel current amplitude compared to wild-type, placing function midway between the functional and knockout states. When the channel cannot adequately regulate lysosomal pH, two downstream failures occur: First, autophagosome clearance is impaired³³ autophagosome clearance is impaired — cellular debris builds up rather than being digested. Second, and most critically for neurodegeneration, alpha-synuclein — the protein that aggregates into Lewy bodies in Parkinson's disease — accumulates in its phosphorylated (aggregation-prone) form. Wild-type TMEM175 overexpression reduces phospho-α-synuclein; M393T overexpression does not. The channel is also considered a druggable target for lysosomal dysfunction in neurodegeneration⁴⁴ druggable target for lysosomal dysfunction in neurodegeneration, with selective inhibitors and activators under active investigation.

The Evidence

The genetic signal is one of the strongest in Parkinson's disease research. Chang et al. 2017 (Nature Genetics) identified the TMEM175 locus with OR 1.23, p=1×10⁻⁵⁰⁵⁵ Chang et al. 2017 (Nature Genetics) identified the TMEM175 locus with OR 1.23, p=1×10⁻⁵⁰ across 26,035 cases and 403,190 controls — one of 17 novel PD risk loci. The Nalls et al. 2019 Lancet Neurology meta-analysis of 37,688 cases and 1.4 million controls⁶⁶ Nalls et al. 2019 Lancet Neurology meta-analysis of 37,688 cases and 1.4 million controls confirmed the locus among 90 independent genome-wide significant signals. Functional studies by Wie et al. (Nature, 2021) quantified the C allele OR at 1.26 [95% CI 1.22–1.31]⁷⁷ Wie et al. (Nature, 2021) quantified the C allele OR at 1.26 [95% CI 1.22–1.31] and found that C carriers in the University of Pennsylvania and PPMI cohorts showed faster motor decline (p=0.032) and faster cognitive decline (p=0.005) after diagnosis. Beyond PD, the Blauwendraat et al. 2019 age-at-onset GWAS⁸⁸ Blauwendraat et al. 2019 age-at-onset GWAS (28,568 cases) found rs34311866 p.M393T is the primary coding signal for earlier PD onset. The Krohn et al. 2022 RBD GWAS (Nature Communications)⁹⁹ Krohn et al. 2022 RBD GWAS (Nature Communications) then identified TMEM175 as one of five loci for REM sleep behavior disorder — a prodromal synucleinopathy — shared across RBD, PD, and dementia with Lewy bodies.

Practical Actions

Carriers of the C allele cannot fix the M393T variant, but they can support the cellular processes that compensate for reduced lysosomal function. The principal strategy is maintaining autophagic flux — the rate at which cells clear protein waste — through targeted supplementation and lifestyle choices. Trehalose, a disaccharide that activates the TFEB transcription factor independently of mTOR, has documented preclinical effects on TMEM175-dependent clearance pathways. Spermidine similarly induces autophagy via eIF5A hypusination. Urolithin A (a gut metabolite of ellagic acid) activates mitophagy and has Phase II trial data in humans. These are not generic supplements — they specifically address the autophagy-lysosomal axis impaired by M393T. Neurological monitoring for early-onset cognitive or motor changes is warranted, particularly given evidence of accelerated decline after diagnosis.

Interactions

TMEM175 sits in the same autophagy-lysosomal pathway¹⁰¹⁰ autophagy-lysosomal pathway as GBA1 (glucocerebrosidase) — the strongest known genetic risk factor for PD (rs76763715, N370S). Both genes affect lysosomal function and alpha-synuclein clearance, but through distinct mechanisms: TMEM175 at the pH-regulation step, GBA1 at the enzymatic glucosphingolipid-hydrolysis step. Carriers of risk alleles in both genes may face compounded impairment of lysosomal alpha-synuclein clearance. rs2736990 (SNCA intron 4) increases alpha-synuclein expression levels — a separate upstream contributor to the same aggregation cascade. The combination of elevated substrate (SNCA) and impaired clearance (TMEM175) represents a convergent risk architecture worth capturing as a compound interaction candidate.

The GLP-1 receptor¹¹ GLP-1 receptor
Glucagon-like peptide-1 receptor, the molecular target of Ozempic, Wegovy, and Saxenda is the direct drug target for some of the most prescribed medications in modern medicine: semaglutide (Ozempic, Wegovy), liraglutide (Saxenda, Victoza), and exenatide (Byetta). Unlike most pharmacogenomic variants that affect drug metabolism enzymes, rs3765467 changes the drug target itself — replacing arginine with glutamine at position 131 in the receptor's extracellular binding domain. This variant is strikingly population-specific: carried by about 21% of East Asians but fewer than 0.3% of Europeans.

The Mechanism

Position 131 sits in exon 4 of GLP1R²² exon 4 of GLP1R
The extracellular N-terminal domain where GLP-1 and its drug analogues make initial contact with the receptor, within the ligand-binding pocket that makes direct contact with GLP-1 and its pharmaceutical mimics. Arginine at this position carries a positive charge that participates in electrostatic interactions stabilizing ligand binding. The glutamine substitution removes this charge, altering receptor conformation and downstream cAMP signaling³³ cAMP signaling
Cyclic adenosine monophosphate, the key second messenger that triggers insulin release from pancreatic beta cells. In beta-cell models, the variant receptor shows significantly reduced glucose-stimulated insulin secretion and increased apoptosis⁴⁴ significantly reduced glucose-stimulated insulin secretion and increased apoptosis
Li et al. GLP1R SNPs rs3765467 and rs10305492 affect beta-cell insulin secretory capacity. DNA Cell Biol, 2020. However, in living human carriers, the picture is paradoxically reversed — healthy heterozygotes show over 100% greater beta-cell responsivity to GLP-1⁵⁵ healthy heterozygotes show over 100% greater beta-cell responsivity to GLP-1
Sathananthan et al. Common genetic variation in GLP1R and insulin secretion. Diabetes Care, 2010, suggesting compensatory mechanisms that amplify the signal in vivo.

The Evidence

The strongest genetic evidence comes from a large East Asian exome-wide study⁶⁶ large East Asian exome-wide study
Kwak et al. Nonsynonymous variants in PAX4 and GLP1R are associated with type 2 diabetes. Diabetes, 2018 of over 17,000 individuals, which showed the A allele is protective against type 2 diabetes at genome-wide significance (OR 0.84, P = 3.55 x 10^-8). This is consistent with the enhanced insulin secretion seen in carriers.

For drug response, two key findings stand out. A Korean pharmacogenomic study⁷⁷ Korean pharmacogenomic study
Han et al. A genetic variant in GLP1R is associated with response to DPP-4 inhibitors. Medicine, 2016 of 246 T2D patients found A allele carriers had twice the odds of responding to DPP-4 inhibitors (OR 2.00, 95% CI 1.03-3.89), with greater HbA1c reduction (1.3% vs 0.9%, P = 0.022). In contrast, a Chinese prospective cohort⁸⁸ Chinese prospective cohort
Guan et al. Association between GLP1R gene polymorphism and treatment response to GLP1R agonists. Eur J Clin Pharmacol, 2022 of 156 patients found the wild-type GG genotype had significantly better HbA1c reduction on GLP-1 agonists (1.7% vs 0.8%, P = 0.002) and higher rates of reaching target HbA1c (50.9% vs 23.8%).

This apparent contradiction likely reflects different drug mechanisms: DPP-4 inhibitors raise endogenous GLP-1 to physiological levels (where the variant receptor's enhanced sensitivity is advantageous), while GLP-1 agonists deliver pharmacological doses that may overwhelm the altered receptor. Supporting this, A allele carriers also show increased gastrointestinal side effects on liraglutide⁹⁹ increased gastrointestinal side effects on liraglutide
Long et al. Eur J Clin Pharmacol, 2022 (P = 0.007), with a dose-dependent relationship between A allele count and nausea severity.

Practical Implications

The core clinical question for carriers is which GLP-1-based therapy will work best. The evidence suggests that if the primary goal is glycemic control, DPP-4 inhibitors (sitagliptin, saxagliptin) may be more effective than expected for A allele carriers. If a GLP-1 agonist (semaglutide, liraglutide) is chosen — particularly for weight loss — slower dose titration and close monitoring of both gastrointestinal tolerance and glycemic response are warranted.

Interactions

The parallel GLP1R variant rs6923761 (Gly168Ser) also modifies GLP-1 agonist response but through a distinct mechanism — primarily affecting gastric emptying rate and weight loss magnitude. Carriers of both Arg131Gln and Gly168Ser may have compounded alterations in GLP-1 agonist response affecting both glycemic control and weight loss. The related GIPR variant rs10423928 affects the parallel incretin pathway and may further modify response to dual GIP/GLP-1 agonists like tirzepatide (Mounjaro). The intracellular GLP1R variant rs10305492 (Ala316Thr) also reduces beta-cell signaling and may compound with Arg131Gln to create a more severely impaired receptor profile.

The MTRR gene encodes methionine synthase reductase, a flavoprotein that keeps the methylation cycle running by reactivating methionine synthase (MTR) after oxidative inactivation. Without functional MTRR, MTR can't recycle homocysteine to methionine, and the entire one-carbon methylation machinery stalls. The well-studied MTRR A66G variant (rs1801394) directly alters the protein, but MTRR also carries intronic variants that appear to influence gene regulation in subtler ways. rs3776467 is one such variant — an intronic substitution at position c.401+827 that has no direct effect on the MTRR protein sequence, yet shows a reproducible association with DNA methylation outcomes in specific contexts.

The Mechanism

Because rs3776467 sits within an intron ¹¹ Intronic variants can influence gene expression through effects on splicing, branch point usage, and regulatory element binding without changing the amino acid sequence of the protein, it does not alter the MTRR protein. Its effects are likely regulatory — modulating the level or splicing of MTRR transcripts rather than the enzyme's catalytic activity. The functional consequence of reduced MTRR expression would parallel the missense A66G effect: less efficient B12 reactivation, impaired MTR activity, and downstream effects on homocysteine remethylation and global DNA methylation. The precise regulatory mechanism has not been characterized.

The Evidence

The primary evidence comes from the Lovelace Smokers Cohort²² Lovelace Smokers Cohort
Flores KG et al. Sex-specific association of sequence variants in CBS and MTRR with risk for promoter hypermethylation in the lung epithelium of smokers. Carcinogenesis, 2012, a study of 907 non-Hispanic white smokers examining promoter hypermethylation in lung epithelium. In this cohort, the G allele of rs3776467 was associated with reduced risk for high promoter hypermethylation: OR 0.57 (95% CI: 0.42–0.77, p=0.0003) overall, driven almost entirely by females (females: OR 0.64, 95% CI: 0.49–0.85, p=0.002; males: OR 0.92, 95% CI: 0.57–1.47, p=0.72). The AA genotype — homozygous for the reference allele — was associated with higher methylation risk, while carrying at least one G allele was protective in women.

A colorectal cancer cohort study³³ colorectal cancer cohort study
Wang Y et al. The Roles of MTRR and MTHFR Gene Polymorphisms in Colorectal Cancer Survival. Nutrients, 2022 of 532 CRC patients (Newfoundland, median follow-up 6.4 years) identified significant interactions between rs3776467 and pre-diagnostic alcohol consumption: protective alleles of rs3776467 were associated with superior overall survival, but only in patients consuming below-median alcohol. This interaction suggests the variant's effect on one-carbon metabolism is amplified by lifestyle factors that disrupt folate and methyl-donor homeostasis.

The evidence is currently emerging — two studies, both in specific populations (smokers, CRC patients), with no direct functional validation of the intronic variant's molecular effect and no homocysteine association data. The sex-specific nature of the primary finding limits applicability.

Practical Actions

For carriers of the AA genotype (homozygous reference, most common in Europeans), the primary actionable insight is context-dependent: the elevated methylation risk appears most relevant in the setting of smoking or high alcohol intake that disrupts the one-carbon cycle. Optimizing methylation nutrition — particularly active B12 forms and methylfolate — supports MTRR function regardless of this variant. For women who smoke, this SNP adds to the case for prioritizing methylation support.

Alcohol consumption deserves specific mention: the interaction with rs3776467 and colorectal cancer survival suggests that alcohol's known methylation- disrupting effects may be modulated by this variant. Reducing alcohol intake supports both folate-dependent methylation and the protective effect of the G allele.

Interactions

rs3776467 operates in the same MTRR pathway as the coding variant rs1801394 (A66G). Combined impairment — AA at rs3776467 plus GG at rs1801394 — could theoretically reduce MTRR function through both regulatory and catalytic mechanisms. The upstream MTHFR variants (rs1801133) affect methylfolate supply, and MTR variants (rs1805087) affect the reaction MTRR supports; weakness at multiple points compounds the burden on the methylation cycle. No published study has assessed the combined genotype of rs3776467 with rs1801394.

Every morning, before you eat, your pancreatic beta cells are running a delicate balancing act. Glucokinase phosphorylates incoming glucose to glucose-6-phosphate, signaling the cell to release insulin. G6PC2 — expressed exclusively in beta cells — hydrolyzes that signal molecule back to glucose¹¹ hydrolyzes that signal molecule back to glucose
Hydrolysis of glucose-6-phosphate to glucose and phosphate in the endoplasmic reticulum, creating a futile substrate cycle. The tighter G6PC2 runs this cycle, the higher your fasting blood glucose must rise before the beta cell "sees" the glucose signal and releases insulin. This variant, rs492594, changes amino acid 219 in G6PC2 from valine (Val; G allele) to leucine (Leu; C allele), altering protein abundance and thereby adjusting how strongly this brake is applied.

The Mechanism

G6PC2 is a nine-transmembrane endoplasmic reticulum enzyme that directly opposes glucokinase — the primary beta-cell glucose sensor²² glucose sensor
Glucokinase phosphorylates glucose at a rate proportional to glucose concentration, making it the rate-limiting step for glucose-stimulated insulin secretion. The futile cycle they create wastes ATP but gives the beta cell a tunable sensitivity threshold. The Val219 form (G allele) of G6PC2 is the common enzyme variant and supports full baseline G6PC2 expression. The Leu219 form (C allele) shows reduced protein abundance via proteasomal degradation³³ reduced protein abundance via proteasomal degradation in cell-based experiments, effectively lowering the brake and allowing the beta cell to respond to glucose at a slightly lower concentration. Animal studies confirm this dose-response logic: complete deletion of G6pc2 in mice lowers fasting blood glucose by 14–16%⁴⁴ lowers fasting blood glucose by 14–16% without changing fasting insulin, because the beta cells now become sensitive at a lower glucose threshold — the insulin release curve shifts leftward.

Position 219 lies within a putative cholesterol recognition amino acid consensus (CRAC) motif⁵⁵ cholesterol recognition amino acid consensus (CRAC) motif
A transmembrane domain sequence that can interact with cholesterol; its presence suggests G6PC2 activity may be membrane-environment dependent. In detergent micelle experiments the Val219 and Leu219 forms show comparable enzymatic activity, but in intact microsomal membrane preparations — which better reflect the in vivo ER environment — the Leu219 variant has lower effective activity, consistent with the reduced protein abundance observed in cellular assays.

The Evidence

The definitive characterization of rs492594 as an independent fasting-glucose signal came from Mahajan et al. 2015⁶⁶ Mahajan et al. 2015
Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus. PLoS Genetics, 2015, a study of up to 33,231 non-diabetic Europeans. After conditioning on the lead non-coding GWAS variant rs560887, three coding variants — including p.Val219Leu — each showed independent association with fasting glucose. Together they explained an additional 0.2% of phenotypic variance beyond rs560887, bringing the G6PC2 locus to ~1.1% of total fasting glucose variance.

A key haplotype complexity: the Leu219 C allele travels almost exclusively in cis with the glucose-raising G allele at rs560887. This means in population-level analyses the Leu219 allele appears to raise glucose (because rs560887-G dominates the haplotype effect), but conditional analysis and functional data confirm Leu219 is itself glucose-lowering through the protein abundance mechanism. In Asian populations, Hu et al. 2009⁷⁷ Hu et al. 2009
Hu C et al. A genetic variant of G6PC2 is associated with type 2 diabetes and fasting plasma glucose level in the Chinese population. Diabetologia, 2009 found rs492594 C allele nominally associated with higher fasting glucose (0.067 mmol/L per allele, p=0.04) in 3,676 subjects — likely reflecting this same haplotype linkage rather than the intrinsic coding-variant effect.

The broader G6PC2 locus signal (dominated by rs560887) is among the most robust common-variant associations with fasting glucose in the human genome, replicated in hundreds of thousands of individuals across multiple ethnicities⁸⁸ hundreds of thousands of individuals across multiple ethnicities with an effect of approximately +0.07 mmol/L per glucose-raising allele.

Practical Actions

The G6PC2 Val219Leu variant creates a modestly higher fasting glucose setpoint in Val219/Val219 (GG) carriers. The overall effect of this specific coding variant is small — on the order of 0.05–0.10 mmol/L per allele — and does not on its own meaningfully raise type 2 diabetes risk. However, fasting glucose sits on a continuum, and small chronic elevations contribute to cumulative glycemic burden over decades. For GG homozygotes, the most directly relevant interventions are those that lower fasting glucose through beta-cell glucose sensing: time-restricted eating (which lowers overnight fasting glucose), regular aerobic exercise (which upregulates skeletal muscle glucose uptake and lowers the glucose threshold needed for insulin release), and avoidance of late-evening carbohydrate loads that elevate glucose during the early fasting period.

Interactions

rs492594 sits at the same gene locus as rs560887, the strongest common-variant determinant of fasting glucose (~1% of FBG variance). The two variants are in partial linkage disequilibrium and have been shown to have conditionally independent effects. The non-coding rs560887 has a larger per-allele effect and should be interpreted alongside rs492594. The G6PC2 locus as a whole interacts additively with GCK variants (e.g. GCK rs1799884) and MTNR1B fasting glucose variants — individuals carrying risk alleles at multiple glycemic loci show compounded effects on fasting glucose and T2D risk. G6PC2 also interacts with glucokinase activity in the shared glucose-cycling substrate cycle; any factor that reduces glucokinase activity (e.g. GCK haploinsufficiency) amplifies the relative importance of G6PC2 in setting the fasting glucose threshold.

Deep inside the hypothalamus, a cluster of roughly 20,000 neurons called the suprachiasmatic nucleus (SCN)¹¹ suprachiasmatic nucleus (SCN)
The brain's master circadian clock, located in the hypothalamus above the optic chiasm; it generates and coordinates ~24-hour biological rhythms throughout the body fires in near-perfect 24-hour cycles, orchestrating sleep, hormone release, and metabolism across every cell in the body. Keeping those neurons synchronized with each other — not just cycling individually — requires a molecular conductor. RGS16²² RGS16
Regulator of G-protein Signaling 16; a protein that accelerates the inactivation of G-protein alpha subunits, terminating cAMP signaling pulses is that conductor.

The rs516134 variant sits approximately 20 kilobases downstream of the RGS16 gene, in a regulatory region that influences how much RGS16 the SCN produces. Carriers of the C allele — the minor allele at this position — tend to wake earlier, feel alert sooner after rising, and perform best in the morning. This makes rs516134 the top replicated chronotype hit in human genetics, having emerged independently in three major genome-wide association studies spanning nearly 700,000 people.

The Mechanism

RGS16 exerts its circadian influence by gating cAMP³³ cAMP
Cyclic AMP (cyclic adenosine monophosphate), a second messenger that amplifies signals from G-protein-coupled receptors; in the SCN, timed cAMP pulses coordinate neuron-to-neuron communication production in the SCN. In the intact clock, RGS16 protein levels rise and fall over the 24-hour cycle, creating a time window each day during which cAMP can accumulate. This rhythmic cAMP pulse synchronizes the dorsomedial SCN neurons (which drive the rest of the body) with the ventrolateral neurons (which receive light input from the retina).

Doi et al. (2011)⁴⁴ Doi et al. (2011)
Doi M et al. Circadian regulation of intracellular G-protein signalling mediates intercellular synchrony and rhythmicity in the suprachiasmatic nucleus. Nature Communications, 2011 showed that when RGS16 is deleted in mice, the circadian cAMP rhythm collapses entirely — and the behavioral circadian period lengthens. A longer internal period means the clock runs slow relative to the 24-hour day, causing the animal (and, by analogy, the human) to drift toward later and later timing — exactly the phenotype associated with low RGS16 activity.

The rs516134 C allele appears to support higher regulatory-region activity, boosting RGS16 expression, tightening cAMP gating in the SCN, and shortening the effective period toward a morning-shifted chronotype. The molecular details of how the variant changes transcription factor binding at this regulatory element remain under active investigation.

The Evidence

The RGS16 locus has the distinction of being the most strongly replicated single locus in human chronotype genetics. Three independent large-scale GWAS, each using different populations and methods, have all converged on this region.

Jones et al. (2016)⁵⁵ Jones et al. (2016)
Jones SE et al. Genome-Wide Association Analyses in 128,266 Individuals Identifies New Morningness and Sleep Duration Loci. PLoS Genetics, 2016 analyzed 128,266 UK Biobank participants and identified rs516134 as the lead SNP at the RGS16 locus, with the C allele conferring an odds ratio of 1.21 (95% CI 1.15–1.27) for morningness at P=3×10⁻¹².

Hu et al. (2016)⁶⁶ Hu et al. (2016)
Hu Y et al. GWAS of 89,283 individuals identifies genetic variants associated with self-reporting of being a morning person. Nature Communications, 2016 independently studied 89,283 23andMe participants and found the same locus — represented by the linked variant rs12736689 — as the single most significant chronotype hit at P=7×10⁻¹⁸. Seven of the 15 significant loci fell near known circadian genes, with RGS16 the strongest.

The definitive meta-analytic confirmation came from Jones et al. (2019)⁷⁷ Jones et al. (2019)
Jones SE et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nature Communications, 2019, which expanded the catalog of chronotype loci from 24 to 351 in 697,828 individuals. The pathway analysis implicated cAMP signaling, circadian regulation, and retinal/hypothalamic expression — all converging on the biology explained by RGS16. Using Mendelian randomization, the study showed that being a morning person is causally associated with better mental health outcomes.

Practical Implications

For carriers of TT (the common genotype), circadian timing is close to the population average — not sharply morning or evening, but with a gentle evening lean compared to C allele carriers. The practical implication is awareness: your biological clock has no strong push toward morningness, so environmental factors (light exposure, meal timing, sleep scheduling) matter more in shaping your daily rhythm.

For carriers of one or two C alleles, the clock runs slightly faster, making it easier to wake early and fall asleep earlier. This is an advantage in most modern work schedules but can become a liability when evening social or professional demands conflict with an early-dimming internal clock. Evening light exposure and slightly later meal timing can extend alertness into the evening when needed.

Light therapy is the most evidence-based intervention for chronotype adjustment in either direction. Morning bright light (10,000 lux) reinforces early timing; evening blue-light reduction prevents unwanted advance for C allele carriers who want to stay up later.

Interactions

rs516134 acts within the same circadian feedback network as variants in CLOCK (rs1801260), PER3 (rs5751876), and the VIP receptor gene. These SNPs operate at different nodes of the circadian oscillator: CLOCK affects transcription factor stability, PER3 affects the negative feedback arm, and RGS16 affects intercellular synchrony via cAMP. Carriers of evening-tendency alleles at multiple loci may experience additive chronotype shifts beyond what any single SNP predicts.

The GPR176–Gz–RGS16 axis is also under investigation for its relationship to human chronotype variation more broadly (PMID 28502923), and several nominally associated variants upstream of RGS16 have been identified in the larger GWAS datasets that may refine the functional signal at this locus.

Endothelial lipase (EL) is an enzyme secreted by vascular endothelial cells that hydrolyzes the phospholipid coat of HDL particles¹¹ HDL particles
high-density lipoprotein — the "good cholesterol" responsible for reverse cholesterol transport from arteries to the liver. Higher endothelial lipase activity degrades HDL faster, lowering both HDL particle count and size. The LIPG gene encodes this enzyme, and rs6507931 is an intronic variant that modulates its expression — with the T allele associated with altered HDL dynamics, particularly under sedentary conditions.

The Mechanism

rs6507931 sits in intron 24 of LIPG (c.1155-108, transcript variant 2) on chromosome 18q21.1. As an intronic variant it does not change the amino acid sequence of the EL protein, but it likely affects splicing efficiency or transcriptional regulation of LIPG expression. Higher LIPG expression means more phospholipid hydrolysis of HDL particles, producing smaller, cholesterol-depleted HDL remnants and reducing overall HDL-C. The T allele tags a haplotype associated with this pattern of increased EL activity, especially when physical activity levels are low — aerobic exercise is known to suppress LIPG expression in striated muscle tissue, protecting HDL from excessive degradation.

The Evidence

The primary evidence for rs6507931 comes from the GOLDN study²² GOLDN study
Smith CE et al. Physical inactivity interacts with an endothelial lipase polymorphism to modulate high density lipoprotein cholesterol in the GOLDN study. Atherosclerosis, 2009, a community-based family study of 1,123 White adults. Participants with the TT genotype who logged high daily screen time (≥2.6 hours) showed lower total HDL-C, reduced large HDL particle concentrations, smaller HDL particle sizes, and elevated small LDL concentrations compared to CT and CC carriers at the same activity level. The effect reached statistical significance (P<0.05) across multiple HDL measures and was more pronounced in women than men.

Halverstadt et al.³³ Halverstadt et al.
Halverstadt A et al. High-density lipoprotein-cholesterol, its subfractions, and responses to exercise training are dependent on endothelial lipase genotype. Metabolism, 2003 studied 83 sedentary adults aged 50–75 who underwent aerobic exercise training. At baseline, CT/TT carriers showed lower HDL(2NMR)-C (12±1.0 vs 17±1.1 mg/dL, P=.002) and lower integrated HDL subfractions. After training, CC homozygotes gained 4.4 mg/dL HDL-C versus only 1.9 mg/dL in CT/TT carriers (P=.04), indicating that the T allele also blunts the HDL response to aerobic exercise.

Vergeer et al.⁴⁴ Vergeer et al.
Vergeer M et al. Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT. Atherosclerosis, 2010 examined rs6507931 in relation to coronary artery disease and deep vein thrombosis. While an initial DVT association (OR 2.04) appeared in one cohort, it could not be replicated, confirming this variant is best classified as a modifier of HDL metabolism rather than a direct cardiovascular risk allele under all conditions.

Practical Actions

The clearest actionable implication of the T allele is that regular aerobic activity is especially important for maintaining HDL-C and HDL particle quality. Exercise suppresses LIPG expression in skeletal and cardiac muscle — T allele carriers who remain sedentary lose this protective downregulation and experience greater HDL degradation. Specifically, high-intensity aerobic activity (cycling, running, swimming) at ≥150 minutes per week has been shown to elevate HDL-C and HDL particle size in LIPG-variant carriers. Omega-3 fatty acids (EPA/DHA) support HDL particle remodeling through a complementary mechanism independent of LIPG activity.

Monitoring the fasting lipid panel — specifically HDL-C and ideally HDL particle size via NMR lipoprotein analysis — provides the most informative tracking for TT individuals, because total HDL-C alone may underestimate the shift toward smaller, less cardioprotective HDL particles.

Interactions

The coding variant rs2000813 (Thr111Ile, T111I) in LIPG exon 3 is the most studied functional variant in this gene and affects EL enzyme activity directly. Carriers of the rs2000813 minor allele (Ile111) show modest HDL-C elevation. rs6507931 and rs2000813 are in linkage disequilibrium in some populations and were studied together in the Hutter et al. haplotype analysis of Japanese Americans (PMID 16023652). The combined haplotype effect on HDL subfractions and apolipoprotein AI levels exceeded either variant alone.

The PPARG gene encodes PPARγ¹¹ PPARγ
Peroxisome Proliferator-Activated Receptor Gamma — a nuclear receptor that controls adipocyte differentiation, fat storage, insulin sensitisation, and lipid metabolism throughout the body, the master regulator of fat-cell biology. The gene has multiple isoforms generated from distinct promoters. The C-689T variant (rs7649970) sits in the P2 promoter — the one that exclusively drives expression of the PPARγ2 isoform²² PPARγ2 isoform
PPARγ2 is distinguished from PPARγ1 by a 28-amino-acid N-terminal extension and is expressed almost exclusively in adipose tissue, where it is the dominant regulator of adipogenesis and insulin sensitisation, which is predominant in adipose tissue and is the isoform studied in the landmark Pro12Ala literature. Unlike Pro12Ala (rs1801282), which changes the receptor protein itself, C-689T changes how much of the protein gets made in the first place.

The Mechanism

The C-689T polymorphism is a C-to-T transition at position -689 in the PPARγ2 P2 promoter, within a region that contains a putative GATA transcription factor³³ GATA transcription factor
GATA factors (GATA2, GATA3) are zinc-finger transcription factors that bind GATA DNA sequences and regulate gene expression in adipose, hematopoietic, and endothelial cells binding site. Meirhaeghe et al. (2005)⁴⁴ Meirhaeghe et al. (2005)
Meirhaeghe A et al. Study of a new PPARgamma2 promoter polymorphism and haplotype analysis in a French population. Mol Genet Metab, 2005 demonstrated that GATA2 and GATA3 proteins bind the wild-type C-689 site but fail to bind the mutated T-689 site. The key consequence: the T allele renders the P2 promoter less active at baseline, resulting in reduced PPARγ2 expression in adipose tissue. Reduced PPARγ2 impairs adipocyte differentiation and insulin sensitisation capacity, shifting the metabolic balance toward higher circulating LDL-cholesterol, elevated triglycerides, and atherogenic lipid profiles.

The Evidence

The discovery study by Meirhaeghe et al. (2005)⁵⁵ Meirhaeghe et al. (2005)
Meirhaeghe A et al. Study of a new PPARgamma2 promoter polymorphism and haplotype analysis in a French population. Mol Genet Metab, 2005 examined 1,155 French subjects and found that T allele carriers had significantly elevated body weight and LDL-cholesterol concentrations compared with CC homozygotes. A haplotype analysis showed that when C-689T interacts with the C1431T and Pro12Ala variants in a specific haplotype combination, the association with higher LDL and body weight is amplified.

Two Chinese Han studies quantified the cardiovascular risk directly. Li et al. (2008)⁶⁶ Li et al. (2008)
Li JP et al. Study on the association of -689C/T polymorphism in the PPARgamma2 promoter with myocardial infarction. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2008 enrolled 194 myocardial infarction patients and 693 controls and found the T allele was an independent risk factor for MI (OR 2.13, 95% CI 1.21–3.74, P = 0.009) after adjusting for traditional risk factors. T allele carriers also showed significantly elevated total cholesterol. Li et al. (2017)⁷⁷ Li et al. (2017)
Li JP et al. Functional variant of C-689T in the peroxisome proliferator-activated receptor-γ2 promoter is associated with coronary heart disease in Chinese nondiabetic Han people. Chin Med Sci J, 2017 extended this to 455 CHD patients and 693 controls without CHD, finding the T allele independently associated with CHD (OR 1.67, 95% CI 1.03–2.71, P = 0.037) and confirmed elevated total cholesterol in T carriers.

A European replication came from Dallongeville et al. (2009)⁸⁸ Dallongeville et al. (2009)
Dallongeville J et al. Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease. PPAR Res, 2009 using the PRIME study cohort (249 CHD cases, 494 controls; middle-aged men from France and Northern Ireland). TT homozygotes showed OR 3.43 (95% CI 0.96–12.27, P = 0.058) — statistically marginal owing to the rarity of TT, but biologically consistent with the Chinese data. In a haplotype study of 1,155 French subjects, Meirhaeghe et al. (2005, Diabetes)⁹⁹ Meirhaeghe et al. (2005, Diabetes)
Meirhaeghe A et al. Association between peroxisome proliferator-activated receptor gamma haplotypes and the metabolic syndrome in French men and women. Diabetes, 2005 found that a haplotype carrying the T allele was enriched in metabolic syndrome cases (OR up to 2.47).

Practical Implications

The T allele is carried by roughly 13% of Europeans and 17% of Africans, making CT heterozygotes (~23% of Europeans) a sizeable group for whom LDL monitoring and lipid management are specifically warranted. The TT homozygote (roughly 2% of the population globally) carries the highest expression deficit but is too rare for well-powered homozygote-specific trials. The primary actionable markers are LDL-cholesterol and total cholesterol — both consistently elevated in T allele carriers across populations.

Interactions

rs7649970 is one of four common PPARG variants that co-segregate in haplotype blocks. The most clinically relevant interactions are with rs1801282 (Pro12Ala) and rs3856806 (C1431T). The G-T-Ala haplotype (rs10865710 G / rs7649970 T / rs1801282 Ala) was associated with the highest LDL and body weight burden in the Meirhaeghe 2005 cohort. Additionally, rs7649970 and rs10865710 act through independent mechanisms — rs10865710 disrupts a CREB2 enhancer element while rs7649970 disrupts GATA binding in the PPARγ2 P2 promoter — meaning carriers of risk alleles at both loci face compounded suppression of PPARγ expression via separate molecular paths.

The CHI3L1 gene encodes YKL-40, a chitinase-like glycoprotein that functions as a biomarker and mediator of tissue inflammation. Elevated YKL-40 is a consistent feature of active asthma, allergic airway disease, and cardiovascular inflammation; levels track with disease severity across all three domains. The CHI3L1 locus on chromosome 1q32.1 contains a cluster of genetic variants — each contributing independently to how much YKL-40 your body produces. rs2297839 is an intronic variant at this locus that co-associates with lower YKL-40 levels, adding a third independent regulatory signal alongside the well-characterized promoter (rs4950928) and upstream eQTL (rs10399931) variants.

The Mechanism

rs2297839 sits within the body of the CHI3L1 gene at chr1:203183056 (GRCh38), approximately 3.7 kb from the main promoter variant rs4950928. The variant is annotated as intronic on the minus-strand gene. The precise molecular mechanism by which rs2297839 influences CHI3L1 expression has not been published in isolation — it was identified as a tag SNP among 15 CHI3L1 variants in a population study rather than through a dedicated functional assay. However, its co-classification with four other CHI3L1 variants (rs10399931, rs1538372, rs2071580, rs4950928) as YKL-40-lowering alleles in Xu et al. 2021¹¹ Xu et al. 2021
Xu T et al. Association of CHI3L1 gene variants with YKL-40 levels and hypertension incidence. J Cell Mol Med, 2021 indicates it is part of the same regulatory architecture. The T allele at rs2297839 is consistently associated with lower circulating YKL-40, mirroring the effect of protective alleles at rs4950928 and rs10399931.

Intronic variants can modulate gene expression through several mechanisms: altering splicing enhancer or silencer sequences²² splicing enhancer or silencer sequences
Intronic regulatory elements that recruit splicing factors, affecting which exons are included in the final mRNA, disrupting chromatin loop anchor points, or tagging functional variants in linkage disequilibrium. Given that the Guerra et al. birth cohort study found that CHI3L1 alleles linked to lower YKL-40 are associated with higher DNA methylation at five CpG sites, epigenetic mediation is a plausible route for rs2297839 as well.

The Evidence

The primary evidence for rs2297839 comes from a nested case-control study by Xu et al.³³ nested case-control study by Xu et al.
Xu T et al. Association of CHI3L1 gene variants with YKL-40 levels and hypertension incidence: A population-based nested case-control study in China. J Cell Mol Med, 2021 of 507 matched case-control pairs within a Chinese prospective cohort. Among 15 CHI3L1 tag SNPs, rs2297839 was one of five variants associated with lower YKL-40 levels. In the male sub-analysis, heterozygous and rare homozygous T-allele carriers had a significantly lower risk of hypertension compared with major homozygote (CC) carriers (OR 0.49, 95% CI 0.26–0.91).

The biological plausibility rests on the well-established role of YKL-40 in vascular inflammation. Lee et al. 2010⁴⁴ Lee et al. 2010
Lee C-G et al. Role of breast regression protein-39/YKL-40 in asthma and allergic responses. J Allergy Clin Immunol, 2010 demonstrated that YKL-40 activates macrophages, promotes Th2 polarization, and drives tissue remodeling — mechanisms relevant to both airway disease and atherosclerosis. Lower genetically-determined YKL-40 should therefore dampen inflammatory signaling across multiple tissue compartments.

It is important to note that rs2297839 has only one direct study, and the hypertension association was limited to male subjects in a Chinese cohort. Independent replication in diverse populations and dedicated functional characterization are needed before the evidence level can be upgraded beyond emerging.

Practical Actions

For CC homozygotes, the genotype represents the common YKL-40-higher baseline, shared by approximately 64% of people globally. Serum YKL-40 is the most direct readout of combined CHI3L1 genetic status — useful for tracking inflammatory activity in asthma, COPD, or cardiovascular workups.

For CT and TT carriers, the T allele is associated with a lower inflammatory setpoint at this locus. In a clinical YKL-40 result, T-allele carriers at rs2297839 — especially when combined with protective alleles at the promoter (rs4950928 GG) or eQTL (rs10399931 TT) — are likely to show lower-than-average values that reflect their genetics rather than a pathological deficiency.

Interactions

rs2297839 operates within the same CHI3L1 regulatory cluster as rs4950928 (promoter, the strongest YKL-40 determinant), rs10399931 (upstream regulatory, acts via a post-transcriptional mechanism), and rs872129 (a third independent eQTL signal confirmed by conditional analysis in Chou et al. 2024). The intronic variant rs12141494 adds a fourth independent signal that specifically affects airway tissue YKL-40 and lung function severity in asthma. Each variant in this cluster represents a partial contribution to the genetic YKL-40 set-point — carriers of protective alleles at multiple CHI3L1 variants benefit from additive suppression of this inflammatory axis.